STELLA PHARMA CORPORATION
TTSE:4888407.00
JPY
-37.00
(-8.33%)
ISIN
JP3399680002
Return %
Stock
S&P 500
1Y
21.13
14.20
3Y
45.36
81.12
5Y
-25.18
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Koki Uehara
- Full Time Employees
- 47
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- ORIX Kouraibashi Building Osaka OS Japan 541-0043
- IPO Date
- Apr 22, 2021
- Website
- stella-pharma.co.jp
- Similar Companies
- Business
- Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals, with a primary focus on boron-based drugs used in Boron Neutron Capture Therapy (BNCT). The company's key product is Steboronine® (also known as SPM-011), a boron-containing drug developed for BNCT that targets cancer cells in head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. The active pharmaceutical ingredient in Steboronine® is Borofalan (10B), which contains highly purified Boron-10. Stella Pharma also explores the development and commercialization of innovative cancer therapies using BNCT technology. Founded in 2007, the company is headquartered in Osaka, Japan. In addition to its BNCT drug development, Stella Pharma provides a range of pharmaceutical products focused on chronic disease treatments, including cardiovascular drugs, antidiabetics, sedatives, gastrointestinal drugs, analgesics, anti-inflammatory agents, antiallergic drugs, antibiotics, antifungals, antivirals, antitussive drugs, and nutritional supplements. The company targets healthcare markets in Japan and internationally through partnerships and alliances that support regulatory approvals and technology transfers. Recent company developments include ongoing efforts toward the regulatory approval and commercialization of BNCT as a novel cancer treatment, positioning Stella Pharma as a pioneer in this innovative medical technology. The company maintains strategic partnerships and continues expanding its BNCT product portfolio for clinical application. These efforts aim to establish BNCT as a standard cancer treatment option, reflecting a significant strategic shift toward advanced oncology therapies within Stella Pharma's portfolio. Stella Pharma operates primarily in the healthcare and biotechnology sectors, serving medical institutions and cancer treatment centers. The company remains committed to advancing therapeutic approaches through its proprietary boron compounds and BNCT platform, maintaining ongoing research collaborations with domestic and international academic and industrial partners. Overall, Stella Pharma Corporation is a specialized pharmaceutical company focused on BNCT drug development, supported by a broad product portfolio addressing chronic diseases, headquartered in Osaka with a founding year of 2007, continuously advancing innovative cancer therapies and strategic growth in the biopharmaceutical industry.